Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic
colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor
(EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR
(ECD-EGFR).